Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Imiquimod + Sonidegib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Imiquimod | Aldara | Imiquimod acetate | ||
| Sonidegib | Odomzo | NVP-LDE225|Erismodedgib|LDE-225 | SMO Inhibitor 16 | Odomzo (sonidegib) is a small molecule inhibitor of SMO, which inhibits proliferation (PMID: 23935925). Odomzo (sonidegib) is FDA approved for use in patients with locally advanced basal cell carcinoma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03534947 | Phase II | Imiquimod + Sonidegib Sonidegib | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (SONIB) | Recruiting | AUS | 0 |